

## Disclosures

### Personal Commercial (8)

| Company Name         | Relationship Category    | Compensation Level       | Topic Area(s)                       |
|----------------------|--------------------------|--------------------------|-------------------------------------|
| <i>Self</i>          |                          |                          |                                     |
| Abbott Vascular      | Research/Research Grants | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Biosensors           | Research/Research Grants | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Biotronik            | Research/Research Grants | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Boston Scientific    | Research/Research Grants | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Daiichi Sankyo       | Research/Research Grants | Significant (>= \$5,000) | Acute Coronary Syndromes            |
| Donga-ST             | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| Hanmi Pharmaceutical | Research/Research Grants | Significant (>= \$5,000) | Stable Ischemic Heart Disease       |
| Medtronic            | Research/Research Grants | Significant (>= \$5,000) | Invasive CV Angio and Interventions |

### Additional Personal Commercial Disclosures for Education Activities (4)

| Company Name                | Relationship Category | Compensation Level | Topic Area(s)                 |
|-----------------------------|-----------------------|--------------------|-------------------------------|
| <i>Self</i>                 |                       |                    |                               |
| AstraZeneca Pharmaceuticals | Speaker's Bureau      | Modest (< \$5,000) | Acute Coronary Syndromes      |
| Daiichi Sankyo              | Speaker's Bureau      | Modest (< \$5,000) | Acute Coronary Syndromes      |
| Pfizer                      | Speaker's Bureau      | Modest (< \$5,000) | Stable Ischemic Heart Disease |
| Sanofi-Aventis              | Speaker's Bureau      | Modest (< \$5,000) | Acute Coronary Syndromes      |

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name   | Relationship Category                        | Compensation Level       | Topic Area(s) |
|--|--|--------------------------|---------------|
| <i>Self</i>  |  |                          |               |
| the National Evidence-based Healthcare Collaborating Agency, the Ministry of Health & Welfare, Korea | Research/Research Grants<br>‡ SMART-DECISION | Significant (>= \$5,000) |               |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 11/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 11/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 11/17/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.